Kamedis Receives Notice of Allowance for First US Patent on Botanical Eczema Treatment
SAN FRANCISCO, Jan. 15, 2019
SAN FRANCISCO, Jan. 15, 2019 /PRNewswire/ -- Kamedis™, a provider of advanced botanical solutions for chronic skin disorders, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application involving the company's Kamedis Calm Eczema Therapy Cream. The notice signifies that Kamedis will receive patent protection on the product's proprietary combination of traditional Chinese botanicals, which was developed to treat eczema-related inflammation and infection.
Kamedis Calm Eczema Therapy Cream utilizes an exclusive formulation of Chinese Rhubarb, Great Burnet, Tree of Heaven, Baikal Skullcap, Cnidium Fruit and Licorice extracts in conjunction with conventional active and inactive ingredients. It has been clinically proven to reduce eczema flare-ups by 50% in two weeks, providing significant relief for a condition that affects more than 31 million people in the U.S. including one-third of infants.
Each botanical in the Kamedis formula contains multiple components that modulate different physiological mechanisms simultaneously, helping restore the natural barrier that protects skin against bacteria and irritants. This healthy skin ecosystem helps repair the dryness, itchiness and inflammation associated with eczema. No steroids, parabens, dyes or fragrances are used, minimizing the risk of adverse effects.
A double-blind, randomized clinical trial scheduled for completion in early 2019 is examining the specific role of the product's botanical ingredients in the healing process. The trial is comparing the effectiveness of Kamedis Calm Eczema Therapy Cream, the Kamedis product without the Chinese botanical formulation, and a competitive OTC brand in mitigating eczema symptoms among 108 U.S. children and adults. It marks the first U.S. clinical study designed to determine the efficacy of traditional Chinese botanicals in commercial dermatologic treatments.
The Kamedis product line also includes botanical-based treatment regimens for acne, dandruff and dry feet. The pending patent on the Kamedis Calm Eczema Therapy will be the first U.S. patent received by the company.
Kamedis develops effective, dermatologist-tested, botanical skincare products for a variety of chronic skin conditions including eczema, acne, dandruff, seborrheic dermatitis, psoriasis, dry skin and itchy/irritated skin. Launched in Israel in 2003 and now sold worldwide, the company's products are based on extensive scientific research and development that included testing hundreds of traditional Chinese medicine botanicals and their combinations. The botanicals are produced in an ISO 13485 and ISO 9001-certified manufacturing facility ensuring quality and production consistency of botanical extracts. The unique extraction technique is developed to maximize formulation potency. All final products have been validated by dermatologists, are backed by dozens of clinical trials, and have received strong endorsement from consumers. For more information, visit https://kamedis-usa.com or email firstname.lastname@example.org.